Center-Authored Papers

Filters: Author is Kantarjian, Hagop M  [Clear All Filters]
Journal Article
Alvarnas JC, Brown PA, Aoun P, Ballen KK, Barta SK, Borate U, Boyer MW, Burke PW, Cassaday R, Castro JE et al..  2015.  Acute Lymphoblastic Leukemia, Version 2.2015.. Journal of the National Comprehensive Cancer Network : JNCCN. 13(10):1240-79. Abstract
Becker PS, Kantarjian HM, Appelbaum FR, Petersdorf SH, Storer BE, Pierce S, Shan J, Hendrie PC, Pagel JM, Shustov AR et al..  2011.  Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia.. British journal of haematology. 155(2):182-9. Abstract
Walter RB, Kantarjian HM, Huang X, Pierce SA, Sun Z, Gundacker HM, Ravandi F, Faderl SH, Tallman MS, Appelbaum FR et al..  2010.  Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(10):1766-71. Abstract
Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F et al..  2013.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.. Blood. 122(6):872-84. Abstract
Ravandi F, Estey EH, Appelbaum FR, Lo-Coco F, Schiffer CA, Larson RA, Burnett AK, Kantarjian HM.  2012.  Gemtuzumab ozogamicin: time to resurrect? Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30(32):3921-3.
Gu Z, Churchman M, Roberts K, Li Y, Liu Y, Harvey RC, McCastlain K, Reshmi SC, Payne-Turner D, Iacobucci I et al..  2016.  Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia.. Nature communications. 7:13331. Abstract
Kantarjian HM, DeAngelo DJ, Advani AS, Stelljes M, Kebriaei P, Cassaday RD, Merchant AA, Fujishima N, Uchida T, Calbacho M et al..  2017.  Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study.. The Lancet. Haematology. Abstract
Roberts KG, Gu Z, Payne-Turner D, McCastlain K, Harvey RC, Chen I-M, Pei D, Iacobucci I, Valentine M, Pounds SB et al..  2016.  High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. :JCO2016690073. Abstract
Cortes JE, Kantarjian HM, Goldberg SL, Powell BL, Giles FJ, Wetzler M, Akard L, Burke JM, Kerr R, Saleh M et al..  2009.  High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(28):4754-9. Abstract
Baccarani M, Druker BJ, Branford S, Kim D-W, Pane F, Mongay L, Mone M, Ortmann C-E, Kantarjian HM, Radich JP et al..  2014.  Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study.. International journal of hematology. Abstract
Ostronoff F, Othus M, Kantarjian HM, Meshinchi S, Ravandi F, Hendrie PC, Faderl S, Becker PS, Cortes JE, Pagel JM et al..  2013.  A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia.. British journal of haematology. 163(1):130-2.
Tsimberidou A-M, Kantarjian HM, Wen S, Keating MJ, O'Brien S, Brandt M, Pierce S, Freireich EJ, Medeiros JL, Estey E.  2008.  Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia.. Cancer. 113(6):1370-8. Abstract
Brown PA, Shah B, Fathi A, Wieduwilt M, Advani A, Aoun P, Barta SK, Boyer MW, Bryan T, Burke PW et al..  2017.  NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017.. Journal of the National Comprehensive Cancer Network : JNCCN. 15(9):1091-1102. Abstract
Pallera A, Altman JK, Berman E, Abboud CN, Bhatnagar B, Curtin P, DeAngelo DJ, Gotlib J, Hagelstrom TR, Hobbs G et al..  2016.  NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017.. Journal of the National Comprehensive Cancer Network : JNCCN. 14(12):1505-1512. Abstract
Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G et al..  2011.  Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.. Blood. 117(4):1141-5. Abstract
Kantarjian HM, Erba HP, Claxton D, Arellano M, Lyons RM, Kovascovics T, Gabrilove J, Craig M, Douer D, Maris M et al..  2010.  Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(4):549-55. Abstract
Tefferi A, Verstovsek S, Barosi G, Passamonti F, Roboz GJ, Gisslinger H, Paquette RL, Cervantes F, Rivera CE, Deeg HJ et al..  2009.  Pomalidomide is active in the treatment of anemia associated with myelofibrosis.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(27):4563-9. Abstract
Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, Etienne G, Nicolini FE, le Coutre P, Clark RE et al..  2016.  Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.. The Lancet. Oncology. Abstract
Konopleva M, Walter RB, Faderl S, Jabbour E, Zeng Z, Borthakur G, Huang X, Kadia T, Ruvolo P, Feliu JB et al..  2014.  Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myeloid Leukemia.. Clinical cancer research : an official journal of the American Association for Cancer Research. 20(8):2226-35. Abstract
Tsimberidou A-M, Kantarjian HM, Wen S, O'Brien S, Cortes J, Wierda WG, Koller C, Pierce S, Brandt M, Freireich EJ et al..  2008.  The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients.. Clinical cancer research : an official journal of the American Association for Cancer Research. 14(3):721-30. Abstract
Becker PS, Kantarjian HM, Appelbaum FR, Storer B, Pierce S, Shan J, Faderl S, Estey EH.  2013.  Retrospective comparison of clofarabine versus fludarabine in combination with high dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia.. Haematologica. 98(1):114-18. Abstract
Walter RB, Othus M, Burnett AK, Löwenberg B, Kantarjian HM, Ossenkoppele GJ, Hills RK, van Montfort KGM, Ravandi F, Evans A et al..  2013.  Significance of FAB subclassification of "Acute Myeloid Leukemia, NOS" in the 2008 WHO classification: analysis of 5,848 newly diagnosed patients.. Blood. Abstract
Sekeres MA, Elson P, Kalaycio ME, Advani AS, Copelan EA, Faderl S, Kantarjian HM, Estey EH.  2009.  Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients.. Blood. 113(1):28-36. Abstract
Martinelli G, Oehler VG, Papayannidis C, Courtney R, Shaik NM, Zhang X, O'Connell A, McLachlan KR, Zheng X, Radich J et al..  2015.  Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study. The Lancet Haematology. 2(8):e339-e346. Abstract